Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZENITH High Proteinuria
CTR20241892Phase 3Active
- Sponsor
- AstraZeneca
- Start
- Jun 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of zibotentan, dapagliflozin in chronic kidney disease (CKD), sponsored by AstraZeneca. Started Jun 2024; status: active.
02
Drugs
zibotentandapagliflozin
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on CTR20241892.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20241892.